Drugs / Bisantrene

Trials 4 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT06815575 Apr 2025 → Jul 2027 expected cancer Racura Oncology Ltd Recruiting No outcome recorded
Phase 1 NCT05456269 Jul 2022 → Aug 2023 acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome Racura Oncology Ltd Withdrawn No outcome recorded
Phase 22 trials
Phase 2 NCT04989335 Aug 2021 → Dec 2024 acute myeloid leukemia Sheba Medical Center Unknown No outcome recorded
Phase 2 NCT03820908 Jul 2019 → May 2020 acute myeloid leukemia, disease related to hematopoietic stem cell transplant Sheba Medical Center Completed No outcome recorded

Evidence & citations 15 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as Bisantrene “multiple ascending doses of RC220 bisantrene formulation alone and in combination with fixed dose doxorubicin” NCT06815575
3

NCT04989335

NCT03820908

NCT05456269

Known as Bisantrene dihydrochloride ChEMBL registry synonym — accepted as the source's own label CHEMBL25336
Known as Bisantrene hcl ChEMBL registry synonym — accepted as the source's own label CHEMBL25336
Known as BISANTRENE HYDROCHLORIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL25336
Known as Bisantreno ChEMBL registry synonym — accepted as the source's own label CHEMBL25336
Known as CL 216,942 ChEMBL registry synonym — accepted as the source's own label CHEMBL25336
Known as NSC-337766 ChEMBL registry synonym — accepted as the source's own label CHEMBL25336
Known as Orange crush ChEMBL registry synonym — accepted as the source's own label CHEMBL25336
Known as RC220 “multiple ascending doses of RC220 bisantrene formulation alone and in combination with fixed dose doxorubicin” NCT06815575
Known as Xantrene “Study of Xantrene® (Bisantrene) in combination with Fludarabine and Clofarabine as Salvage Therapy for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)” NCT04989335
Known as Zantrene ChEMBL registry synonym — accepted as the source's own label CHEMBL25336
Action Inhibit “Alpha-ketoglutarate-dependent dioxygenase FTO inhibitor” CHEMBL25336
Modality Small molecule CHEMBL25336
Route Intravenous “high dose intravenous (IV) bisantrene” NCT05456269
Target FTO “Alpha-ketoglutarate-dependent dioxygenase FTO inhibitor” CHEMBL25336